Assembly BiosciencesASMB +10.25%32 Return-on-Tangible-Equity is -17.92% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,205 Biotechnology companies, Assembly Biosciences ranks better than 73.78% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Assembly Biosciences's annualized net income for the quarter that ended in Mar. 2026 was $-36.32 Mil. Assembly Biosciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $202.68 Mil. Therefore, Assembly Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -17.92%.
The historical rank and industry rank for Assembly Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
ASMB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -107.92 Med: -74.74 Max: -5.04
Current: -5.04
During the past 13 years, Assembly Biosciences's highest Return-on-Tangible-Equity was -5.04%. The lowest was -107.92%. And the median was -74.74%.
ASMB's Return-on-Tangible-Equity is ranked better than 73.78% of 1205
companies
in the Biotechnology industry
Industry Median: -42.47
vs ASMB: -5.04
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Assembly Biosciences Return-on-Tangible-Equity Related Terms
Assembly Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs MDXG, AGMB, TRAX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Assembly Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -17.92% mean?
Assembly Biosciences (ASMB) has a Return-on-Tangible-Equity of -17.92% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #316 out of 1205 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Assembly Biosciences' Return-on-Tangible-Equity too high?
Assembly Biosciences' current Return-on-Tangible-Equity is -17.92%. Based on the distribution chart, Assembly Biosciences ranks #316 out of 1205 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Return-on-Tangible-Equity compare to MDXG and AGMB?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #316 out of 1205 companies for Return-on-Tangible-Equity. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Return-on-Tangible-Equity is -17.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Return-on-Tangible-Equity of -17.92%. The current Return-on-Tangible-Equity is -17.92%. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Return-on-Tangible-Equity is -17.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
